NYSEAMERICAN:HEB

Hemispherx BioPharma Stock Forecast, Price & News

$2.26

-0.08 (-3.42 %)

(As of 03/3/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.22

Now: $2.26▼

$2.38

50-Day Range N/A

52-Week Range

$1.69

Now: $2.26▼

$14.81

Volume1.46 million shs

Average Volume102,599 shs

Market Capitalization$5.52 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Headlines

Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd
October 1, 2020 | bloomberg.com

Hemispherx Biopharma, Inc. to Webcast, Live, at VirtualInvestorConferences.com November 2
July 23, 2020 | www.bloomberg.com

Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards
May 24, 2020 | www.bloomberg.com

Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update
May 12, 2020 | www.bloomberg.com

Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology
April 25, 2020 | www.bloomberg.com

Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination
March 11, 2020 | www.bloomberg.com

Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone
March 6, 2020 | www.bloomberg.com

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing
March 3, 2020 | www.bloomberg.com

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS
August 23, 2019 | finance.yahoo.com

Hemispherx Biopharma EPS beats by $0.65
August 15, 2019 | seekingalpha.com

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials
August 15, 2019 | finance.yahoo.com

Is Hemispherx Biopharma, Inc.'s (NYSEMKT:HEB) CEO Pay Justified?
August 9, 2019 | finance.yahoo.com

Hemispherx Bio up 24% premarket on encouraging Ampligen data
August 8, 2019 | seekingalpha.com

Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®
August 8, 2019 | finance.yahoo.com

Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribution Agreement Disclosed in a Recent SEC Filing
August 3, 2019 | finance.yahoo.com

Hemispherx down 21% on stock sales deal
July 22, 2019 | seekingalpha.com

Hemispherx Biopharma, Inc. Discusses Clinical Development and Competitive Advantage in New SNNLive Video Interview on StockNewsNow.com
July 2, 2019 | finance.yahoo.com

Hemispherx Biopharma CFO Adam Pascale Announces Retirement
June 28, 2019 | finance.yahoo.com

Have Insiders Been Buying Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Shares?
June 24, 2019 | finance.yahoo.com

Hemispherx Biopharma Inc (HEB) Exec. Vice Chairman/CEO/Pres. Thomas K. ...
June 21, 2019 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNYSEAMERICAN:HEB

Previous SymbolNYSE:HEB

CUSIPN/A

CIK946644

Webwww.hemispherx.net

Phone+1-407-2718516

Employees31

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares2,442,000

Market Cap$5.52 million

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.46 out of 5 stars

Medical Sector

1608th out of 1,968 stocks

Biotechnology Industry

86th out of 125 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Hemispherx BioPharma.

2.3 Community Rank

Outperform Votes
Hemispherx BioPharma has received 202 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Hemispherx BioPharma has received 231 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Hemispherx BioPharma has received 53.35% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote “Outperform” if you believe HEB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HEB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Hemispherx BioPharma does not currently pay a dividend.
Dividend Growth
Hemispherx BioPharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hemispherx BioPharma insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$2.26

-0.08 (-3.42 %)

(As of 03/3/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive HEB News and Ratings via Email

Sign-up to receive the latest news and ratings for HEB and its competitors with MarketBeat's FREE daily newsletter.

Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions

What stocks does MarketBeat like better than Hemispherx BioPharma?

Wall Street analysts have given Hemispherx BioPharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hemispherx BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) issued its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter.
View Hemispherx BioPharma's earnings history.

When did Hemispherx BioPharma's stock split? How did Hemispherx BioPharma's stock split work?

Hemispherx BioPharma's stock reverse split on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 10th 2019. An investor that had 100 shares of Hemispherx BioPharma stock prior to the reverse split would have 2 shares after the split.

Who are Hemispherx BioPharma's key executives?

Hemispherx BioPharma's management team includes the following people:

Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 66)
Mr. Adam Pascale, Chief Financial Officer (Age 71)
Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 68)
Mr. Wayne S. Springate, Sr. VP of Operations (Age 48)
Ms. Ellen Lintal, Chief Accounting Officer

Who are some of Hemispherx BioPharma's key competitors?

Some companies that are related to Hemispherx BioPharma include ImmuPharma (IMM), AorTech International (AOR), Quest PharmaTech Inc. (QPT.V) (QPT), Ceapro (CZO), Midatech Pharma (MTPH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), Crescita Therapeutics (CTX), Kane Biotech Inc. (KNE.V) (KNE), Devonian Health Group (GSD), Realm Therapeutics (RLM), Nuformix (NFX), ValiRx (VAL), Pascal Biosciences (PAS), Naturally Splendid Enterprises (NSP) and Medicure (MPH).
View all of HEB's competitors.

What other stocks do shareholders of Hemispherx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Biocept (BIOC), (GDPMQ) (GDPMQ), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN), Biopharmx (BPMX), CTI BioPharma (CTIC), Advaxis (ADXS), Cytori Therapeutics (CYTX) and Frontier Communications (FTR).

What is Hemispherx BioPharma's stock symbol?

Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."

How do I buy shares of Hemispherx BioPharma?

Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hemispherx BioPharma's stock price today?

One share of HEB stock can currently be purchased for approximately $2.26.

How much money does Hemispherx BioPharma make?

Hemispherx BioPharma has a market capitalization of $5.52 million.

How many employees does Hemispherx BioPharma have?

Hemispherx BioPharma employs 31 workers across the globe.

What is Hemispherx BioPharma's official website?

The official website for Hemispherx BioPharma is www.hemispherx.net.

Where are Hemispherx BioPharma's headquarters?

Hemispherx BioPharma is headquartered at 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States.

How can I contact Hemispherx BioPharma?

Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.

This page was last updated on 3/4/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here